Amit Khera, M.D.
Amit Khera, M.D., Director of UT Southwestern’s Preventive Cardiology Program, co-authored a widely circulated editorial in the New England Journal of Medicine that captured the impact of the SELECT trial, which made headlines in November at the annual AHA Scientific Sessions conference.
The trial showed that once-weekly injections of semaglutide reduced the risk of major cardiac events by 20% in patients with overweight or obesity who had CVD but not diabetes. With obesity reaching epidemic proportions in the U.S., the trial shows “we are in a new era of treating obesity and cardiometabolic risk with a growing armamentarium of options,” Dr. Khera wrote in the widely circulated editorial.